Recently, it has been shown that EGFR mutation type, Ct-DNA, and co-mutations may serve as better prognostic factors for establishing a prognostic model for NSCLC patients receiving EGFR-TKI therapy [11,12,13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.